These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31220392)

  • 1. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA.
    Alpuente A; Gallardo VJ; Torres-Ferrus M; Alvarez-Sabin J; Pozo-Rosich P
    Eur J Neurol; 2019 Dec; 26(12):1464-1470. PubMed ID: 31220392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
    J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study.
    Alpuente A; Gallardo VJ; Torres-Ferrús M; Álvarez-Sabin J; Pozo-Rosich P
    Headache; 2020 Apr; 60(4):677-685. PubMed ID: 32086801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
    Halker Singh RB; Aycardi E; Bigal ME; Loupe PS; McDonald M; Dodick DW
    Cephalalgia; 2019 Jan; 39(1):52-60. PubMed ID: 29722276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal.
    Andreou AP; Trimboli M; Al-Kaisy A; Murphy M; Palmisani S; Fenech C; Smith T; Lambru G
    Eur J Neurol; 2018 Aug; 25(8):1069-e83. PubMed ID: 29617060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Reed ML; Fanning KM; Bostic RC; Lipton RB
    Headache; 2020 Oct; ():. PubMed ID: 33090481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
    J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Serrano D; Pavlovic JM; Manack AN; Reed ML; Turkel CC; Buse DC
    Headache; 2014 May; 54(5):830-49. PubMed ID: 24527745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month.
    Torres-Ferrús M; Quintana M; Fernandez-Morales J; Alvarez-Sabin J; Pozo-Rosich P
    Cephalalgia; 2017 Feb; 37(2):104-113. PubMed ID: 26961321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.